Long-term outcomes of biliary atresia patients surviving with their native livers

Portoenterostomy (PE) has remained as the generally accepted first line surgical treatment for biliary atresia (BA) for over 50 years. Currently, close to half of BA patients survive beyond 10 years with their native livers, and most of them reach adulthood without liver transplantation (LT). Despite normalization of serum bilirubin by PE, ductular reaction and portal fibrosis persist in the native liver. The chronic cholangiopathy progresses to cirrhosis, complications of portal hypertension, recurrent cholangitis or hepatobiliary tumors necessitating LT later in life. Other common related health problems include impaired bone health, neuromotor development and quality of life. Only few high-quality trials are available for evidence-based guidance of post-PE adjuvant medical therapy or management of the disease complications. Better understanding of the pathophysiological mechanisms connecting native liver injury to clinical outcomes is critical for development of accurate follow-up tools and novel therapies designed to improve native liver function and survival.

Automated summary

Portoenterostomy (PE) has been the preferred surgical treatment for biliary atresia (BA) for over 50 years. However, despite the normalization of serum bilirubin, complications such as ductular reaction and portal fibrosis persist in the native liver, leading to cirrhosis and other health issues. There is a lack of high-quality trials guiding post-PE medical therapy or management of complications, highlighting the importance of understanding the pathophysiological mechanisms for better follow-up tools and therapies.